Last reviewed · How we verify
AS-AQ (Carsucam)
AS-AQ is a fixed-dose artemisinin-based combination antimalarial that kills malaria parasites through multiple mechanisms involving artemisinin and amodiaquine.
AS-AQ is a fixed-dose artemisinin-based combination therapy that kills malaria parasites through multiple mechanisms of action. Used for Uncomplicated malaria caused by Plasmodium falciparum, Malaria treatment in endemic regions (particularly sub-Saharan Africa).
At a glance
| Generic name | AS-AQ (Carsucam) |
|---|---|
| Sponsor | Centro de Investigacao em Saude de Manhica |
| Drug class | Artemisinin-based combination therapy (ACT) |
| Target | Plasmodium falciparum (multiple parasite targets) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Parasitology |
| Phase | FDA-approved |
Mechanism of action
Artemisinin derivatives generate reactive oxygen species that damage malaria parasite proteins and DNA, while amodiaquine acts as a quinoline antimalarial that interferes with parasite heme metabolism. The combination provides synergistic parasiticidal activity and helps prevent drug resistance through dual mechanisms of action.
Approved indications
- Uncomplicated malaria caused by Plasmodium falciparum
- Malaria caused by other Plasmodium species susceptible to artemisinin-based combinations
Common side effects
- Nausea
- Vomiting
- Abdominal pain
- Headache
- Dizziness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |